Delhi HC seeks response on Ranitidine safety review

The Delhi High Court has sought responses from health authorities on a PIL seeking a deadline for India's pending safety review of Ranitidine. Concerns involve NDMA, a probable carcinogen. The petitioner seeks a published, reasoned regulatory decision, not a ban. A government subcommittee's report, due in October 2025, remains awaited, according to the court petition.